Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) shares traded up 1% on Thursday . The stock traded as high as $0.42 and last traded at $0.41. 1,660,350 shares changed hands during mid-day trading, an increase of 541% from the average session volume of 258,874 shares. The stock had previously closed at $0.40.
Theriva Biologics Trading Up 1.0%
The firm has a market cap of $3.90 million, a PE ratio of -0.01 and a beta of 0.65. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average price is $0.42 and its two-hundred day moving average price is $0.66.
Theriva Biologics Company Profile
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Theriva Biologics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- General Dynamics Hits New Highs: Why It Might Keep Climbing
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Nike’s Turnaround: If the Shoe Fits, Buy It!
- 3 REITs to Buy and Hold for the Long Term
- NVIDIA Breaks Out to New Highs: What Comes Next?
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
